PsiOxus Therapeutics raises a £25m Series C investment to progress oncolytic virus plus checkpoint inhibitor combination study in metastatic colorectal cancer

OXFORD, UK – 19 May 2015 – PsiOxus Therapeutics Ltd. (PsiOxus), the oncolytic immuno-oncology company, has closed a Series C financing round of £25 million (c$38.5 million) to progress its… read more →